• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:周雪涛,姜文浩,韩玥,冯伟静,曾伟,陈晨.TACE联合仑伐替尼联合MWA治疗中晚期大肝癌的疗效评价[J].药学研究,2023,42(5):345-347,351[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2634次   下载 2560次 本文二维码信息
码上扫一扫!
TACE联合仑伐替尼联合MWA治疗中晚期大肝癌的疗效评价
周雪涛1,姜文浩1,韩玥2,冯伟静1,曾伟1,陈晨1
字体:加大+|默认|缩小-
(1.北京市第二医院外科,北京 100031;2.中国医学科学院北京协和医学院肿瘤医院介入治疗科,北京 100021)
摘要:
目的 评价肝动脉化疗栓塞术(TACE)联合仑伐替尼联合微波消融(MWA)治疗中晚期大肝癌的临床效疗效。方法 选取2018.01—2021.12期间中国医学科学院北京协和医学院肿瘤医院和北京市第二医院收治的中晚期大肝癌患者共73例。其中肝动脉化疗栓塞术联合仑伐替尼联合微波消融治疗的患者36例,为观察组;TACE联合仑伐替尼治疗的患者37例,为对照组,对比两组患者的近期疗效、无进展生存期、总生存率及并发症的发生情况。结果 观察组和对照组在4个月后的疾病有效缓解率分别为72.2%、40.5%,具有显著性差异(P < 0.05)。观察组的中位无进展生存期为18个月,对照组的中位无进展生存期为10个月,两组差异有统计学意义(P < 0.05)。观察组的6、12、18、24、36个月的总生存率分别为97.2%、82.7%、70.1% 、54.1%、22.3%,对照组的 6、12、18、24、36个月总生存率分别为94.6%、66.9%、35.4% 、32.2%、9.7%。观察组总生存率明显高于对照组 (P<0.05)。两组术后并发症发生率差异无统计学意义(P>0.05)。结论 肝动脉化疗栓塞术联合仑伐替尼联合微波消融治疗中晚期大肝癌,可强化疗效并有效延长患者的生存时间。
关键词:  肝癌  肝动脉化疗栓塞术  仑伐替尼  微波消融
DOI:10.13506/j.cnki.jpr.2023.05.011
基金项目:2020北京市西城区优秀人才培养资助(No.2020-XCRC-区卫健工委)
出版日期:2023-05-25
Evaluation of the efficacy of TACE combined with rivatinib combined with MWA in the treatment of advanced large hepatocellular carcinoma
ZHOU Xuetao1,JIANG Wenhao1,HAN Yue2,FENG Weijing1,ZENG Wei1,CHEN Chen1
(1.Department of Surgery, Beijing Second Hospital,Beijing 100031, China;2.Department of Interventional Peking Union Medical College, Chinese Academy of Medical Sciences,Beijing 100021, China)
Abstract:
Objective To evaluate the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with rivatinib and microwave ablation (MWA) in the treatment of advanced large hepatocellular carcinoma.Methods Select 73 patients with advanced large hepatocellular carcinoma admitted to the Peking Union Medical College, Chinese Academy of Medical Sciences and the Second Hospital of Beijing from January 2018 to December 2021. 36 patients were treated with TACE combined with rivatinib and MWA, were set as observation group; 37 patients were treated with TACE combined with rivatinib were set as the control group. The short-term efficacy, progression-free survival, total survival rate and complications of the two groups were compared.Results The effective remission rates of the disease in the observation group and the control group after 4 months were 72.2% and 40.5% respectively, with a significant difference (P<0.05). The median progression-free survival was 18 months in the observation group and 10 months in the control group. There was a significant difference between the two groups (P<0.05). The total survival rates at 6, 12, 18, 24 and 36 months in the observation group were 97.2%, 82.7%, 70.1%, 54.1% and 22.3%, respectively, and the total survival rates at 6, 12, 18, 24 and 36 months in the control group were 94.6%, 66.9%, 35.4%, 32.2% and 9.7% respectively. The total survival rate of the observation group was significantly higher than that of the control group (P<0.05). There was no significant difference in the incidence of postoperative complications between the two groups (P>0.05).Conclusion TACE combined with rivatinib combined with MWA in the treatment of middle and advanced large liver cancer can strengthen the curative effect and effectively prolong the survival time of patients.
Key words:  Hepatocellular carcinoma  Transcatheter arterial chemoembolization  Rivatinib  Microwave ablation
今日访问量:2657    总访问量:55339174
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司